Design, Synthesis, and Anticancer Evaluation of Febuxostat‐Based Triazolyl Derivatives
Archiv der Pharmazie · 2026-06 · 359 (6)
DOI: 10.1002/ardp.70263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 05.06.2026. Verfasst von Yao Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design, Triazoles, Febuxostat. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Scientific Research Fund of Henan University of Science and Technology.
Abstract (Originalsprache)
Febuxostat, a selective xanthine oxidase inhibitor, was modified via 1,2,3‐triazole‐based molecular hybridization to generate a series of derivatives with potential anticancer activity. Among them, compounds 8c and 8e exhibited significant antitumor effects across multiple cancer cell lines, particularly in HepG2 cells, with IC 50 values of 6.96 ± 1.76 and 8.56 ± 1.93 μM, respectively. Colony formation assays confirmed that both compounds markedly inhibited tumor cell proliferation. Annexin V‐FITC/PI and TUNEL assays further demonstrated that 8c and 8e induced DNA damage and apoptosis in HepG2 cells, as shown by increased γ‐H2AX expression and enhanced DNA strand breaks. They also activated intrinsic apoptotic pathways, including the cleavage and activation of caspase‐9, caspase‐3, and PARP. In vivo, nude mouse xenograft experiments validated their antitumor efficacy, with elevated cleaved caspase‐3 levels in tumor tissues. Collectively, these findings indicate that 8c and 8e possess strong therapeutic potential against liver cancer and exhibit promising efficacy and safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
- Department of Pharmacy, the First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
- Centre for Artificial Intelligence-Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao SAR, China.
Förderung
- Scientific Research Fund of Henan University of Science and Technology
Zitieren
APA
Lu, Y., Wang, H., Yan, D., He, B., Guo, J., Hou, X., & Liu, L. (2026). Design, Synthesis, and Anticancer Evaluation of Febuxostat‐Based Triazolyl Derivatives. Archiv der Pharmazie, 359(6). https://doi.org/10.1002/ardp.70263
Vancouver
Lu Y, Wang H, Yan D, He B, Guo J, Hou X, et al. Design, Synthesis, and Anticancer Evaluation of Febuxostat‐Based Triazolyl Derivatives. Archiv der Pharmazie. 2026;359(6). doi:10.1002/ardp.70263
BibTeX
@article{Lu2026,
author = {Lu, Yao and Wang, Han and Yan, Dong and He, Baoyu and Guo, Jingjing and Hou, Xixi and Liu, Ling},
title = {Design, Synthesis, and Anticancer Evaluation of Febuxostat‐Based Triazolyl Derivatives},
journal = {Archiv der Pharmazie},
year = {2026},
volume = {359},
number = {6},
doi = {10.1002/ardp.70263}
}
EUVIMED